-
Posted by
Two Blokes Apr 16 -
Filed in
Stock
-
2 views
Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity.
